Business Context and Reporting Period
NLS Pharmaceutics Ltd., a Swiss foreign private issuer, furnished this Form 6-K for April 2024. The report was signed and filed on April 8, 2024.
Material Corporate Change
On April 3, 2024, Anthony S. Walsh, Ph.D. resigned from the company’s board of directors. The company stated that the resignation was not due to any material disagreement regarding operations, policies, or practices.
NLS Pharmaceutics does not intend to appoint a replacement director, resulting in a smaller board.
Financial Metrics and Outlook
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, guidance, or other operating and financial metrics. It also does not include new management guidance or an outlook.
Risks, Contingencies, and Unusual Items
The principal disclosed item is the board resignation and the decision not to replace the departing director. No additional risks, contingencies, or unusual financial items are described in the filing.
The report is incorporated by reference into the company’s specified Form F-3 registration statements, subject to later filings or reports that may supersede it.
Investor Verification Points
- Verify the current composition, size, and independence of the board following Mr. Walsh’s resignation.
- Review subsequent SEC filings for any change in the decision not to replace the director.
- Consult the company’s annual report and other filings for financial performance, liquidity, financing needs, and business outlook, none of which are provided here.
- Confirm the applicable registrant: the filing identifies NLS Pharmaceutics Ltd., not Newcelx Ltd.